Answers are grounded in this paper and cite their sources.
Hybrid approach improves ligand-target binding predictions in drug discovery, highlighting quantum pharmacology's implications.
Recent advances in quantum machine learning (QML) have opened new pathways for accelerating early-stage drug discovery through molecular representation in Hilbert space [1]–[3]. In this work, we present a hybrid quantum–classical framework that integrates quantum kernel estimation and variational quantum neural networks (QNNs) for ligand–target binding prediction [4], [5].A synthetic dataset reflecting the statistical behavior of the BindingDB database [6] was constructed to evaluate quantum descriptors and kernel performance under controlled conditions. The proposed quantum feature maps translate seven key molecular descriptors—molecular weight (MW), logP, hydrogen bond donors (HBD), acceptors (HBA), rotatable bonds (RB), aromatic rings (AR), and topological polar surface area (TPSA)—into entangled qubit states [7], [8].Comparative analyses with classical baselines (SVR, Random Forest, and deep neural networks) revealed that quantum embeddings achieve competitive predictive accuracy (RMSE ≈ 0.06) with improved stability under bootstrap resampling [9]. Quantum kernel alignment and sensitivity studies demonstrated that aromaticity and polarity jointly determine the representational power of QML models [10].Beyond performance, we emphasize Explainable Quantum Pharmacology (EQP)—a paradigm in which interpretability, reproducibility, and physicochemical causality are as essential as accuracy [11].Our findings establish a reproducible, interpretable, and computationally efficient foundation for hybrid QML pipelines in molecular modeling, paving the way for next-generation AI-driven drug discovery.
No takes yet. Share an insight, caveat, or question.
Volkan Erol (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: